Back to Search
Start Over
Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
- Source :
- JAMA: Journal of the American Medical Association; 1/3/2007, Vol. 297 Issue 1, p43-51, 9p, 1 Diagram, 4 Charts, 2 Graphs
- Publication Year :
- 2007
-
Abstract
- This article focuses on a placebo-controlled phase 3 study of the effectiveness of the drug, pexelizumab, as an adjunct to percutaneous transliminal coronary intervention (PCI) in the treatment of patients with acute ST-elevation myocardial infarction. Patients received either placebo or pexelizumab prior to PCI. The main outcome measures were all-cause mortality up to the 30th day, death up to the 90th day and either death, cardiogenic shock or congestive heart failure through days 30 and 90. This study determined that mortality was low in the subjects studied and the administration of pexelizumab did not affect mortality rate.
Details
- Language :
- English
- ISSN :
- 00987484
- Volume :
- 297
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- JAMA: Journal of the American Medical Association
- Publication Type :
- Academic Journal
- Accession number :
- 23575185
- Full Text :
- https://doi.org/10.1001/jama.297.1.43